Table 1.
Responses to front-line corticosteroids and number/duration of treatments during the first 6 months after diagnosis in newly diagnosed ITP patients, according to relation to SARS-CoV-2 infection (upper table) and vaccination (lower table). In all patients who required therapy, corticosteroids were used first-line and started at the same time as the diagnosis of ITP.
| inf-ITP (n.5) | no inf-ITP (n.55) | p value | |
|---|---|---|---|
| Patients receiving front-line corticosteroids, n. (%) | 5/5 (100%) | 49/55 (89.1%) | 0.43 |
| Overall response (CR+R), n. (%) | 3/5 (60.0%) | 45/49 (91.9%) | 0.03 |
| CR, n. (%) | 3/5 (60%) | 33/49 (67.3%) | 0.74 |
| Lines of ITP therapies, median (range), n. | 1 (1–3) | 1 (0–5) | 0.75 |
| Duration of ITP therapies, median (range), days | 45 (31–149) | 56 (0–180) | 0.42 |
| Patients with ongoing ITP therapy after 6 months from therapy start, n. (%) | 1/5 (20%) | 17/49 (34.7%) | 0.51 |
| vax-ITP (n.13) | no vax-ITP (n.47) | p value | |
| Patients receiving front-line corticosteroids, n. (%) | 11/13 (84.6%) | 43/47 (91.5%) | 0.47 |
| Overall response (CR+R), n. (%) | 11/11 (100%) | 37/43 (86.0%) | 0.19 |
| CR, n. (%) | 7/11 (63.5%) | 29/43 (67.4%) | 0.81 |
| Lines of ITP therapies, median (range), n. | 2 (0–3) | 1 (0–5) | 0.06 |
| Duration of ITP therapies, median (range), days | 150 (0–180) | 54 (0–180) | 0.04 |
| Patients with ongoing ITP therapy after 6 months from therapy start, n. (%) | 7/11 (63.6%) | 11/43 (25.6%) | 0.02 |
CR: Complete Response; R: Response.